Floatz logo

Cladribine

Multiple Sclerosis, Relapsing-Remitting

Uppsala UniversitySmall moleculePhase 4 / ApprovedActive
BBB
76/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
73/ 100
Competitive Position
81/ 100

Competitive context

79 Active assets in the Multiple Sclerosis, Relapsing-Remitting cohort.

Asset / SponsorPhaseRating
Fingolimod
TG Therapeutics, Inc.
Phase 4A
Natalizumab
Biogen
Phase 4BBB
Glatiramer
University Hospital, Montpellier
Phase 4BBB
Interferon ?1 (human fibroblast protein moiety)
Biogen
Phase 4BBB
Ocrevus
Biocad
Phase 4BBB

View all 50 →

Same molecule, other indications

Cladribine is also rated in:

lymphoblastic lymphomaDormant
BBB
Indicative ·
75 / 100
View asset →
multiple sclerosisDormant
BBB
Indicative ·
72 / 100
View asset →
myeloid neoplasmDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →